Biomarker ID | 454 |
PMID | 19773444 |
Year | 2009 |
Biomarker | MIC-1 (Macrophage inhibitory cytokine 1); A1BG a-1B-glycoprotein1 precursor; VTNC (Vitronectin precursor); RNPEP (Arginyl aminopeptidase); FETUA (Fetuin A) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Cell Lines |
Subjects | Humans |
Regulation | Upregulated in Docetaxel- resistant PC3-Rx cells [(MIC-1 Macrophage inhibitory cytokine 1 (2.4 fold); A1BG a-1B-glycoprotein1 precursor (1.9 fold) ; VTNC Vitronectin precursor (1.7 fold); RNPEP Arginyl aminopeptidase (1.6 fold); FETUA Fetuin A (1.6 fold)] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-TAp63 pathway, p73 transcription factor network,p53 signaling pathway,BDNF signaling pathway |
Experiment | Docetaxel-sensitive PC3 cells Vs Docetaxel- resistant PC3-Rx cells |
Type of Biomarker | Potential Predictive |
Cohort | Docetaxel-sensitive PC3 cells and Docetaxel resistant PC3-Rx cells developed by Docetaxel dose escalation were selected for this analysis |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | iTRAQ-mass spectrometry |
Clinical | Yes |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Human patient cohort |
Technical Name | GDF15 |